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Objective: The objective of this study was to determine the sequential CT find-
ings of controlled hepatocellular carcinoma (HCC) with main portal vein (MPV)
thrombosis with the use of transcatheter arterial chemoembolization and addition-
al intra-arterial cisplatin infusion. 
Materials and Methods: From January 2004 to September 2006, 138 patients
with HCC invading MPV were referred to the angiography unit of our institution for
chemoembolization and additional intra-arterial cisplatin infusion. Until August
2008, seven (5%) of 138 patients were followed-up and found not to have tumor
recurrence. CT scans were retrospectively reviewed by two radiologists, focusing
on the following parameters: the extent of portal vein thrombosis, the diameter of
the affected portal vein, and enhancement of portal vein thrombosis.
Results: The extent of portal vein thrombosis at the initial presentation was
variable: left portal vein (LPV) and MPV (n = 1), right portal vein (RPV) and MPV
(n = 3), as well as RPV, LPV and MPV (n = 3). The extent and diameter of the
affected portal vein decreased during follow-up examinations. In addition, the
degree of enhancement for tumor thrombi and serum alpha-feto-protein levels
decreased after the transcatheter arterial chemoembolization. Portal vein throm-
bosis was found to be completely resolved in one patient, whereas residual
thrombus without viability was persistent in six patients.
Conclusion: If chemoembolization is effective in patients with HCC that
invades the portal vein, the extent and enhancement of portal vein thrombosis is
reduced, but residual thrombosis frequently persists for months or years, without
evidence of a viable tumor.
ranscatheter arterial chemoembolization is a widely performed procedure
for inoperable hepatocellular carcinomas (HCCs) (1, 2). Recent meta-
analysis result has shown that chemoembolization can improve patient
survival (3). However, only a few case reports have described HCCs with main portal
vein (MPV) invasion that have been cured by chemoembolization (4-6). Moreover,
chemoembolizations in patients with MPV tumor thrombosis have the potential risk to
cause hepatic insufficiency and the survival benefit of chemoembolization has not
been proven (6-8). The use of continuous hepatic arterial infusion chemotherapy,
interferon-α -based chemotherapy, and three-dimensional conformal radiotherapy has
shown favorable results in patients with portal vein tumor thrombosis (9, 10).
Recently, we have attempted a chemoembolization with additional intra-arterial
cisplatin infusion in patients with portal vein tumor thrombosis (11). Seven HCC cases
Jeong-Hee Yoon, MD
1
Hyo-Cheol Kim, MD
1
Jin Wook Chung, MD
1
Jung-Hwan Yoon, MD
2
Hwan Jun Jae, MD
1
Jae Hyung Park, MD
1
Index terms:
Portal vein thrombosis
Hepatocellular carcinoma
Chemoembolization
DOI:10.3348/kjr.2010.11.1.69
Korean J Radiol 2010;11:69-74
Received May 21, 2009; accepted 
after revision September 7, 2009.
1Department of Radiology, Seoul National
University College of Medicine, Institute of
Radiation Medicine, Seoul National
University Medical Research Center, and
Clinical Research Institute, Seoul National
University Hospital, Seoul 110-744,
Korea; 
2Department of Internal Medicine
and Liver Research Institute, Seoul
National University College of Medicine,
Seoul 110-744, Korea
Address reprint requests to:
Jin Wook Chung, MD, Department of
Radiology, Seoul National University
Hospital, 101 Daehang-ro, Jongno-gu,
Seoul 110-744, Korea.
Tel. (822) 2072-2584
Fax. (822) 743-6385
e-mail: chungjw@snu.ac.kr
T
CT Findings of Completely Regressed
Hepatocellular Carcinoma with Main
Portal Vein Tumor Thrombosis after
Transcatheter Arterial
Chemoembolizationwith MPV tumor thrombosis were cured. The goal of this
study was to determine the sequential CT findings of the
seven patients with controlled HCCs accompanied by MPV
thrombosis, which was treated by transarterial chemoem-
bolization and additional intra-arterial cisplatin infusion.
MATERIALS AND METHODS
Patients
From January 2004 to September 2006, 1,359 patients
who were newly diagnosed with HCC were referred to the
angiography unit of our institution for chemoembolization.
For 138 out of 1,359 patients, MPV tumor thrombosis was
evident at initial presentation. Until August 2008, seven
patients (5%) have been followed-up without tumor
recurrence. The seven patients were all male with an age
range of 32-72 years (mean age, 53 years). Six patients
were hepatitis B carriers, while one was a hepatitis C
carrier. In all cases, a diagnosis of HCC was made based on
laboratory testing (e.g., elevated α -fetoprotein levels and
expression of viral markers) with typical CT and
angiographic findings. All patients had received repeated
chemoembolization, and one patient received additional
radiation therapy for portal vein thrombosis. The criteria
of ‘complete remission’ are as follows: 1) no enhancement
on a portion in the liver, suggesting the presence of a
viable tumor as seen on a CT image, 2) no hypervascular
staining as detected on angiography, 3) a serum α -fetopro-
tein level less than 20 ng/mL, 4) no metastasis detected on
a CT image. The institutional review board approved this
study and patient informed consent was waived due to the
retrospective nature of the study.
Multi-Detector Row CT
Every patient had undergone a CT examination every
two or three months. The CT examinations were
performed using various multi-detector row CT scanners.
The scanners included a four-detector row CT scanner (MX
8000, Philips Medical Systems, Cleveland, OH), an eight-
detector row CT scanner (Light Speed Ultra, GE Medical
Systems, Milwaukee, WI), a 16-detector row CT scanner
(Sensation 16, Siemens, Erlangen, Germany), and a 64-
detector row CT scanner (Brilliance 64, Philips Medical
Systems). All patients who received chemoembolization at
our institution underwent CT scanning before each
chemoembolization session.
The respective scanning parameters used for the 4-, 8-,
16- and 64-multidetector row CT scanners included the
following: (detector configurations) 4 × 2.5, 8 × 1.25, 16
× 0.75, and 64 × 0.625 mm; (slice thickness) 3.2, 2.5, 3,
and 3 mm; (reconstruction intervals) 3, 2.5, 3, and 2 mm;
(table speed) 12.5, 13.5, 24 and 46 mm/rotation; (rotation
time) 0.5-0.75 seconds.
Each CT examination included four phases that consisted
of unenhanced images, hepatic arterial, portal venous, and
equilibrium phases. After first acquiring unenhanced liver
images in the craniocaudal direction, contrast medium
(Iopromide, Ultravist 370; Schering, Berlin, Germany) was
administered, which followed by a 30-mL sterile saline
flush using a power injector (Multi-level CT; Medrad,
Pittsburgh, PA). Contrast medium and saline solution were
injected at 3 mL/sec through an 18-gauge plastic
intravenous catheter placed in an antecubital vein.
Contrast medium volume (delivered at 2 mL/kilogram
body weight) varied from 100-130 mL. Hepatic arterial
phase scan delays were 11-17 seconds after the descending
aorta enhancement reached 100 Hounsfield units (HU), as
measured using a bolus-tracking technique. Portal venous
phase interscan delays were 20-30 seconds. The equilib-
rium phase commenced 180 seconds after completing the
administration of contrast medium.
Methods of Chemoembolization
All angiographic examinations were performed by an
experienced interventional radiologist (with 15 years of
experience). Conventional chemoembolizations were
performed as selectively as possible through the segmental
or subsegmental arteries using a microcatheter
(Microferret; Cook, Bloomington, IN or Progreat; Terumo,
Tokyo, Japan). Initially, an iodized oil (Lipiodol; Andre
Guerbet, Aulnay-sous-Bois, France) and doxorubicin
hydrochloride (Adriamycin RDF; Ildong Pharmaceutical,
Seoul, Korea) emulsion was administered into the feeders.
The iodized oil volume ranged from 3 mL to 10 mL, and
the amount of doxorubicin ranged from 20 mg to 50 mg.
Gelatin sponge particles (Gelfoam; Upjohn, Kalamazoo,
MI) that were mixed with mitomycin (Mitomycin-10;
Kyowa Hakko Kogyo, Tokyo, Japan) and contrast material
were administered into the feeders until the blood flow
had nearly completely stopped. Every effort was made to
seek and catheterize small arterial feeders that supplied
tumor thrombi. Additional superselective cisplatin
(Cisplan; Donga, Seoul, Korea) infusion was started after
obtaining near complete stasis of vascular flow of the
target arteries. Cisplatin was prepared as a solution at a
concentration of 0.5 mg/mL, and the drug was infused as
selectively as possible at a rate of 5-10 mL/min. The total
amount of cisplatin ranged from 70 mg to 100 mg accord-
ing to the patient body weight.
Analysis
All CT scans were reviewed, and four CT examinations
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initial CT scan, the CT scan after the first chemoemboliza-
tion, the CT scan after the last chemoembolization session,
and the last CT scan during follow-up. CT scans were
retrospectively reviewed by two radiologists and focused
on the following parameters: the extent of portal vein
thrombosis, the diameter of the affected portal vein (MPV,
right portal vein [RPV] and left portal vein [LPV]),
enhancement of portal vein thrombosis, and the existence
of a collateral vein as depicted on CT scans. Enhancement
of portal vein thrombosis was assessed by the use of a
region of interest (ROI) measurement, which was an
average value of three ROI values of 20 mm
2 in the tumor
thrombus. In the case of iodized oil uptake for portal vein
thrombosis, an ROI measurement was not possible.
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AB
Fig. 1. Imaging findings are presented for 64-year-old man with hepatocellular carcinoma accompanied by main portal vein invasion.
A. CT scan of portal venous phase obtained at initial presentation shows ill-defined tumor (arrows) in liver parenchyma and thrombus
(arrowhead) in main portal vein. Expansion of portal vein and enhancement of thrombus are evident.
B. One month after initial chemoembolization, tumor (arrow) was spotted with iodized oil in liver parenchyma and tumor thrombus
(arrowhead) laden along with iodized oil in right anterior portal vein on portal phase.
C. Also noted is decreased extent and diameter of thrombus (arrowhead) in portal vein on same CT scan as B. 
D. CT scan of portal venous phase obtained 34 months after last chemoembolization shows small thrombus (arrow) in right anterior
portal vein. 
CDRESULTS
The mean follow up period was 34 months (range, 25-45
months; median, 33 months) after the initial CT scan, and
26 months (range, 16-40 months; median, 24 months)
after the last chemoembolization session. The median
number of chemoembolization procedures was 3 (range,
2-7), with a two- to four-month interval.
In all cases, the tumors were massive HCCs with MPV
thrombosis as depicted on CT images. The primary tumors
were in the right lobe of the liver (n = 4), in the caudate
lobe (n = 1), and in the portal vein itself (n =2). The extent
of portal vein thrombosis at the initial presentation was
variable; LPV and MPV (n = 1), RPV and MPV (n = 3), as
well as RPV, LPV, and MPV (n = 3). The involved portal
vein was the LPV (n = 4), RPV (n = 6), right anterior portal
vein (RAPV) (n = 6), right posterior portal vein (RPPV) (n
= 6), and MPV (n = 7). The mean diameters of the affected
MPV, RPV and LPV were 17.3, 19.2 and 14.6 mm, respec-
tively. The mean attenuation of the portal vein tumor
thrombosis as depicted on initial CT images was as follows:
45 HU for the precontrast phase, 81.5 HU for the arterial
phase, and 84 HU for the portal phase. A collateral vein
around the gall bladder was noted at the initial presenta-
tion in the four patients.
Based on follow-up studies, the extent and diameter of
the affected portal vein decreased (Fig. 1). Portal vein
thrombosis was present in the LPV (n = 2), RPV (n = 2),
RAPV (n = 5), RPPV (n = 3), and MPV (n = 2) as depicted
on the CT images obtained after the last chemoemboliza-
tion session. Portal vein thrombosis was present in the LPV
(n = 1), RPV (n = 2), RAPV (n = 5), RPPV (n = 3), and
MPV (n = 1), as depicted on the last CT images obtained
during the follow-up examination (Table 1). Whereas
portal vein thrombosis was completely resolved in only
one patient, a residual thrombus without viability was
persistent in six patients. In three patients, segmental
obliteration of the LPV (n = 1), RPV (n = 1), and RAPV (n
= 1) was noted. The mean diameters of the MPV, RPV,
and LPV were 15.4, 15.5 and 12.2 mm after the first
chemoembolization session and 14.1, 9.2, and 7.5 mm
after the last chemoembolization session and 12.8, 8.4, and
7.3 mm as measured at the last follow-up, respectively
(Table 2).
In three patients, the ROI measurement of the portal
vein thrombosis was not possible because of iodized oil
retention. In the four remaining patients, the mean attenu-
ation of portal vein tumor thrombosis after the last
chemoembolization session was 37 HU for the precontrast
phase, 46.5 HU for the arterial phase, and 50 for the portal
phase.
A collateral vein was noted in five patients after the first
session of chemoembolization, whereas a collateral vein
was present in all patients after the last session of
chemoembolization. In two patients, a collateral vein was
present only around the gall bladder. In five patients, a
collateral vein was present around the LPV (n = 1), PRV (n
= 2), as well as the MPV, RPV and LPV (n = 2).
The mean α -fetoprotein level was measured to be 7,512
ng/mL (range, 34-34,100 ng/mL) at initial presentation. In
six patients, the baseline α -fetoprotein level was higher
than 300 ng/mL, which represents a decrease of more than
50% after the first chemoembolization session. In all
patients, the α -fetoprotein level was less than 20 ng/mL
than following the last chemoembolization session.
DISCUSSION
The diagnosis of malignant portal vein thrombosis (PVT)
has been based on characteristic CT findings including an
expansile vein diameter and relatively strong enhancement
or obvious direct invasion by a tumor in the adjacent liver
parenchyma (12-14). In our study, a malignant PVT was
seen with a decreased  portal vein diameter and enhance-
ment of the thrombi after chemoembolization, but residual
thrombi without viability can be persistent for months or
years.
After repeated chemoembolization, the mean diameter
of the affected portal vein significantly decreased.
Especially the RPV, which was involved to the greatest
degree, demonstrated a marked decrease in the diameter
as seen on follow-up CT images. The extent of portal vein
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Table 1. Extent of Portal Vein Thrombosis After
Chemoembolization
Site Initial
After Last  On Last 
Chemoembolization CT scan
Main portal vein 7 2 1
Left portal vein 4 2 1
Right portal vein 6 2 2
Right anterior portal vein 6 5 5
Right posterior portal vein 6 3 3
Table 2. Mean Portal Vein Diameter After
Chemoembolization
Initial Diameter After 1st  Diameter After Final 
Site Diameter  Chemoembolization Chemoembolization 
(mm) (mm) (mm)
Main portal vein 17.3 15.4 12.8
Right portal vein 19.2 15.5 08.4
Left portal vein 14.6 12.2 07.3thrombosis decreased after repeated chemoembolization, if
chemoembolization was found to be effective. However,
the complete resolution of portal vein thrombosis was
observed in only one patient. In six patients, various
degrees of residual thrombosis were present from one to
three years after the last treatment. Obvious enhancement
of PVT, as seen on arterial phase images, indicates viable
tumor thrombosis. However, in three patients, it was not
possible to measure the enhancement of tumor thrombi on
follow-up CT scans after repeated chemoembolization due
to retention of iodized oil in the thrombi. In four patients,
residual thrombi without viability showed little enhance-
ment, as seen on contrast-enhanced CT scans. Thus, portal
vein thrombosis depicted on a follow-up CT scan should
not be diagnosed as a residual viable tumor if the portal
vein thrombosis shows little enhancement and the extent
of thrombosis does not increase.
Spiral CT performed at least four weeks after treatment
is currently accepted as the standard imaging modality for
the assessment of response to treatment for HCCs (15).
Non-enhanced tumoral areas reflect tissue necrosis after
treatment, whereas viable neoplastic cells are recognized
by enhanced areas inside the treated lesions (15). Whereas
the use of iodized oil may diminish the reliability of the CT
scans, the accuracy of MRIs is not affected (15). Thus, a
further investigation of the usefulness of MRI for the
assessment of PVT may be needed.
Some investigators have noted that chemoembolization
was contraindicated for patients with MPV tumor
thrombosis, because of the potential risk of ischemic liver
damage and no survival benefit (8). In contrast, other
authors insisted that chemoembolization might be safely
performed in patients with MPV tumor thrombosis if they
have good hepatic reserve and collateral circulation around
the portal vein (5-7). Chung et al. (6) performed a
chemoembolization on 110 patients with HCC that
invaded the 1st branch of the portal vein or the MPV: The
response rate was 28% and the median survival time was
6 months. In their series, three patients died within one
month after chemoembolization and tumor extent was a
significant factor in predicting the efficacy of therapy. They
insisted that chemoembolization was effective and safe if
the extent of the tumor was limited and liver function was
preserved. Georgiades et al. (5) reported that the mortality
rate within one month was zero in HCC patients with PV
thrombosis, whereas the Child-Pugh score was the
strongest prognostic factor. At our hospital, whereas
chemoembolization is not attempted in the patients with
MPV tumor thrombosis if the patients are classified into
Child-Pugh C class, chemoembolization is strongly
recommended in patients with Child-Pugh A and B class. 
Prominent collateral vessels are known to have protec-
tive properties against acute hepatic failure following
chemoembolization in HCC with MPV tumor thrombus
(7). In our study, however, four patients had collateral
veins around the gall bladder and no patients had collateral
veins around the MPV or first branch of the portal vein at
the initial presentation. Since this study included only well-
controlled patients with MPV tumor thrombosis by
chemoembolization, a paucity of collateral veins in our
study population does not guarantee that chemoemboliza-
tion is safe in HCC patients with MPV thrombosis without
collateral veins. 
Our study had several limitations; first, the tumor
thrombi were not confirmed histopathologically. Second,
only a small number of patients were involved in the
study. Third, we used CT scanning for the evaluation of
residual viable tumors and thus it was not possible to
measure the enhancement of tumor thrombi on follow-up
CT scans after repeated chemoembolizations in three
patients.
In conclusion, if chemoembolization is effective in
patients with an HCC that invades the portal vein, the
extent and enhancement of PVT is reduced, but residual
thrombosis frequently persists months or years without
evidence of a viable tumor.
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